Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.10.17	DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS (RTTNews)
16.10.17	Regeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For Dupilumab (RTTNews)
16.10.17	Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis (PR Newswire)
11.10.17	Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis (PR Newswire)
11.10.17	Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis (PR Newswire)
05.10.17	Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) (PR Newswire)
28.09.17	Sanofi, Regeneron: Dupixent Gets EU Approval To Treat Atopic Dermatitis (RTTNews)
28.09.17	Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union (PR Newswire)
20.09.17	Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS (PR Newswire)
20.09.17	Alnylam Pharma: Patisiran Phase 3 Study Meets Endpoints - Quick Facts (RTTNews)
19.09.17	Huge Supply Shortage Looms for Canada's Newest Industry (PR Newswire)
16.09.17	Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis (PR Newswire)
14.09.17	Sanofi Reports Results Of TAKE CONTROL Study - Quick Facts (RTTNews)
13.09.17	Daily Blood Glucose Measures in Phase 3 Clinical Trials Demonstrated Better Stability with Sanofi's Toujeo® vs. Insulin Glargine 100 Units/mL (PR Newswire)
12.09.17	Global Net Lease, Inc. Announces Successful Completion of its $100 Million Series A Cumulative Redeemable Preferred Stock Offering (PR Newswire)
12.09.17	Sanofi Reports Post-hoc Analysis Of Phase 3 Soliqua 100/33 Trials (RTTNews)
12.09.17	Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL (PR Newswire)
11.09.17	Sanofi, Regeneron: Dupilumab Meets Main Objectives In Late-Stage Asthma Trial (RTTNews)
11.09.17	Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma (PR Newswire)
01.09.17	Sanofi Receives Tentative FDA Approval of Admelog® (insulin lispro injection) 100 Units/mL (PR Newswire)
28.08.17	Sanofi Closes Acquisition Of Influenza Vaccine Developer Protein Sciences (RTTNews)
25.08.17	Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017 (PR Newswire)
23.08.17	ALM Intelligence Names KPMG a Global 'Leader' in Employee Experience Consulting (PR Newswire)
17.08.17	Technical Snapshots for These Drug Makers Stocks -- Pfizer, Eli Lilly, Merck, and Sanofi (PR Newswire)
09.08.17	Sanofi Files Suit In U.S. To Defend Its Patent Rights On Lantus (RTTNews)
31.07.17	Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER (PR Newswire)
31.07.17	Sanofi Q2 Profit Down, Sales Rise; Lifts FY17 Earnings View; Stock Up (RTTNews)
31.07.17	Sanofi Q2 Profit Declines, Sales Rise; Lifts FY17 Business EPS View (RTTNews)
24.07.17	One Step Closer To EU Approval... (RTTNews)
21.07.17	Sanofi Receives CHMP Positive Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
21.07.17	Regeneron, Sanofi Get Positive CHMP Opinion For Dupixent - Quick Facts (RTTNews)
21.07.17	Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
17.07.17	Sanofi Pasteur Ships First of its U.S. Influenza Vaccine Doses for 2017-2018 Season (PR Newswire)
17.07.17	Samuel Adams Launches Brewing the American Dream Collaboration Pack - In Stores This July (PR Newswire)
14.07.17	Emergent BioSolutions To Buy ACAM2000 Business From Sanofi For Up To $125 Mln (RTTNews)
12.07.17	ORMP To Meet With FDA, Second Time's No Charm For OCUL, Panel Backs PFE (RTTNews)
11.07.17	Sanofi To Buy Protein Sciences (RTTNews)
10.07.17	Sanofi Genzyme Reports Results From Phase 2 Open-Label Extension Study (RTTNews)
07.07.17	Alnylam, Sanofi Initiate ATLAS Phase 3 Program With RNAi Therapeutic Fitusiran (RTTNews)
05.07.17	Breakfast Technical Briefing on Drug Makers Stocks -- Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Sanofi (PR Newswire)
27.06.17	Sanofi Announces Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union (PR Newswire)
27.06.17	Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union (PR Newswire)
27.06.17	Regeneron: EC Okays Kevzara To Treat Moderately To Severely Active RA (RTTNews)
27.06.17	Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union (PR Newswire)
15.06.17	Start Your Morning With a Cup of Coffee and an Ounce of Dengue Prevention (PR Newswire)
12.06.17	LXRX Brings Sweet Tidings, PFE's PROSPER Ahead Of Schedule, XBIT Fails To Excite (RTTNews)
12.06.17	Sanofi Announces Results From Two Phase 3b/4 ODYSSEY-DM Trials In Diabetes (RTTNews)
11.06.17	Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia (PR Newswire)
11.06.17	Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia (PR Newswire)
10.06.17	In Senior Adults Treated with Basal Insulin, Switching to Sanofi's Toujeo® Halved Hypoglycemia Risk (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	509.00	0.49 %	K V
Nestle	74.00	-0.05 %	K V
CieFinRichemont	137.90	-0.43 %	K V
Givaudan	3’874.00	-0.56 %	K V
Zurich Insur Gr	527.20	-0.75 %	K V
Sonova Hldg	298.30	-1.49 %	K V
Lonza Grp	544.60	-1.70 %	K V
Logitech Intl	76.90	-1.76 %	K V
Part Grp Hldg	1’283.50	-2.47 %	K V
Holcim	85.22	-2.81 %	K V

mehr

20.12.24		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer
17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung

20.12.24

Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer

17.10.24

Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden

04.10.24

Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar

12.09.24

Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach

11.09.24

Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer

02.09.24

Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert